title: Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II study.
abstract: OBJECTIVE
  Cyclophosphamide is a bifunctional alkylating agent long associated with immune activation. Continuous, uninterrupted, low (so-called metronomic) doses of cyclophosphamide can lead to enhanced immunity against a variety of antigens possibly by targeting regulatory T cells and/or tumor angiogenesis. In this study we tested the observations from animal models and evaluated the safety and efficacy of continuous low dose oral cyclophosphamide in patients with hormone resistant prostate cancer.
  
  
  METHODS
  A total of 80 patients were recruited during a 2-year period and 58 received at least 2 cycles (8 weeks) of 50 mg/m(2) oral cyclophosphamide to be included in the safety and intent to treat analysis.
  
  
  RESULTS
  Metronomic cyclophosphamide was safe and well tolerated, and although lymphopenia (up to grade 3) was observed in a third of all patients, there were no clinical complications. The response rate was 34.5% inclusive of objective and prostate specific antigen (absolute reduction and reduction in prostate specific antigen velocity). The median duration of response was 7.5 months (range 3 to 18).
  
  
  CONCLUSIONS
  Oral cyclophosphamide can be used on a metronomic basis safely in men with hormone resistant prostate cancer. The efficacy, low toxicity, low cost and ease of administration of cyclophosphamide justifies further studies in prostate cancer in combination with other agents.
authors.affiliation: Department of Oncology and Urology, St. George's, University of London, London, UK.
authors.forename: R
authors.initials: R
authors.lastname: Lord
authors.forename: S
authors.initials: S
authors.lastname: Nair
authors.forename: A
authors.initials: A
authors.lastname: Schache
authors.forename: J
authors.initials: J
authors.lastname: Spicer
authors.forename: Navita
authors.initials: N
authors.lastname: Somaihah
authors.forename: V
authors.initials: V
authors.lastname: Khoo
authors.forename: H
authors.initials: H
authors.lastname: Pandha
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000369:Aged, 80 and over; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage* / Q000009:adverse effects; D003520:Cyclophosphamide / Q000008:administration & dosage* / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D006801:Humans; D008297:Male; D008875:Middle Aged; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000401:mortality; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D018906:Antineoplastic Agents, Alkylating; D003520:Cyclophosphamide; D017430:Prostate-Specific Antigen